Low molecular weight heparin use in unexplained recurrent miscarriage

Area of Science:

• Reproductive Medicine
• Thrombosis Research

Background:

• Unexplained recurrent miscarriage (URM) affects a significant number of women.
• Current treatment options for URM have limited success rates.

Purpose of the Study:

• To evaluate the efficacy of low molecular weight heparin (LMWH) in improving live birth rates for patients with URM.
• To compare LMWH treatment against a control group in this patient population.

Main Methods:

• A prospective observational study included 150 women with a history of at least two unexplained first-trimester miscarriages.
• Participants were divided into groups receiving enoxaparin, tinzaparin, or no LMWH treatment.
• Standardized dosages of LMWH were administered, and pregnancy outcomes were monitored.

Main Results:

• The live birth rate was significantly higher in the LMWH group (85%) compared to the control group (66%) (p=0.007).
• No significant difference in live birth rates was observed between enoxaparin and tinzaparin subgroups.
• Maternal and neonatal side effects were not statistically significant across the groups.

Conclusions:

• Thromboprophylaxis with LMWH demonstrates improved live birth rates in women experiencing unexplained recurrent pregnancy loss.
• These promising results warrant confirmation through larger, randomized clinical trials to establish LMWH as a standard treatment for URM.